L. Zou

发表论文 6 篇 · 总被引 109 次 · h-index 3

代表论文

• China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy (2019 · Cancer Communications · 被引 91)
• Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers (2023 · Cancer Communications · 被引 14)
• Clinical review considerations of class I PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation. (2022 · Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 被引 6)
• [Rethinking the marketing strategy of anti-tumor drugs by single-arm trials supported]. (2022 · Zhonghua zhong liu za zhi [Chinese journal of oncology] · 被引 1)
• [Considerations for anti-cancer drug application by single arm trials]. (2018 · Zhonghua zhong liu za zhi [Chinese journal of oncology] · 被引 1)
• 境外授权许可引进抗肿瘤新药临床研发策略的审评考虑 (2022 · Zhongguo fei ai za zhi = Chinese journal of lung cancer)